OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - ASTRAZENECA | Market Closed - Deutsche Boerse AG 12:43:33 20/05/2024 pm IST | ||
| 1.34 EUR | +8.06% |
|
| Current month | -0.74% | ||
| 1 month | -50.55% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 20/24/20 | 1.34 | +8.06% |
| 17/24/17 | 1.24 | -2.36% |
| 16/24/16 | 1.27 | +18.69% |
| 15/24/15 | 1.07 | +4.90% |
| 14/24/14 | 1.02 | +6.25% |
Delayed Quote Deutsche Boerse AG
Last update May 20, 2024 at 12:43 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SH5RR1 |
| ISIN | DE000SH5RR15 |
| Date issued | 24/03/2022 |
| Strike | 13,211 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.97 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.97 € |
|---|---|
| Lowest since issue | 0.96 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
167.9
USD
Spread / Average Target
+9.24%
- Stock Market
- Certificates
- Certificat